American pharmaceutical company Modern reported today that the effectiveness of the covid 19 vaccine it is developing is 94.5%. This was demonstrated by the interim results of the third phase of vaccine clinical trials.
“This positive interim analysis of the third phase of the test gave us the first clinical confirmation that our vaccine can prevent even severe Covid 19 disease,” said Moderna’s CEO. Stephane Bancel.
The effectiveness of the vaccine was demonstrated by the intermediate results of the third phase of clinical trials, in which more than 30,000 people participated. The vaccine is based on informational ribonucleic acid (mRNK). It conveys instructions that stimulate the body’s cells to make proteins to prevent or fight disease.